Long-acting parenteral nanoformulated antiretroviral therapy: Interest and attitudes of HIV-infected patients

Nanomedicine

Volumn 8, Issue 11, 2013, Pages 1807-1813

  Williams, Jennifer ^a   Sayles, Harlan R ^b   Meza, Jane L ^b   Sayre, Patrick ^c   Sandkovsky, Uriel ^a   Gendelman, Howard E ^a,d   Flexner, Charles ^c   Swindells, Susan ^a  

^a UNIVERSITY OF NEBRASKA MEDICAL CENTER   (United States)

^b UNIVERSITY OF NEBRASKA MEDICAL CENTER   (United States)

^c JOHNS HOPKINS UNIVERSITY   (United States)

^d NEBRASKA MEDICAL CENTER   (United States)

Author keywords

AIDS; antiretroviral therapy; HIV; intravenous drug abuse; nanoformulated antiretroviral therapy; nonadherence; substance abuse

Indexed keywords

ANTIRETROVIRUS AGENT; ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT;

ADULT; ADVERSE OUTCOME; AGED; ANTIVIRAL THERAPY; ARTICLE; DRUG COST; DRUG DELIVERY SYSTEM; DRUG USE; FEMALE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LONG ACTING PARENTERAL NANOFORMULATED ANTIRETROVIRAL THERAPY; MAJOR CLINICAL STUDY; MALE; MEDICATION COMPLIANCE; PATIENT ATTITUDE; PRIORITY JOURNAL; ADOLESCENT; HIV INFECTIONS; MIDDLE AGED; STATISTICS AND NUMERICAL DATA; YOUNG ADULT;

ADOLESCENT; ADULT; AGED; ANTI-HIV AGENTS; FEMALE; HIV INFECTIONS; HUMANS; MALE; MIDDLE AGED; PATIENT ACCEPTANCE OF HEALTH CARE; YOUNG ADULT;

EID: 84887248504     PISSN: 17435889     EISSN: 17486963     Source Type: Journal    
DOI: 10.2217/nnm.12.214     Document Type: Article

References (17)

1. Paterson DL, Swindells S, Mohr J et al. Adherence to protease inhibitor therapy and outcomes in patients with HIV infection. Ann. Intern. Med. 133(1), 21-30 (2000). (Pubitemid 30432540)
2. Swindells S, Flexner C, Fletcher CV, Jacobson JM. The critical need for alternative antiretroviral formulations, and obstacles to their development. J. Infect. Dis. 204(5), 669-674 (2011).
3. Pautler M, Brenner S. Nanomedicine: promises and challenges for the future of public health. Int. J. Nanomedicine 5, 803-809 (2010).
4. Roy U, Mcmillan J, Alnouti Y et al. Pharmacodynamic and antiretroviral activities of combination nanoformulated antiretrovirals in HIV-1-infected human peripheral blood lymphocyte-reconstituted mice. J. Infect. Dis. 206(10), 1577-1588 (2012).
5. Balkundi S, Nowacek AS, Veerubhotla RS et al. Comparative manufacture and cell-based delivery of antiretroviral nanoformulations. Int. J. Nanomedicine 6, 3393-3404 (2011).
6. Baert L, Van 't Klooster G, Dries W et al. Development of a long-acting injectable formulation with nanoparticles of rilpivirine (TMC278) for HIV treatment. Eur. J. Pharm. Biopharm. 72(3), 502-508 (2009).
7. Jackson Akil EL, Tjai J, Seymour N et al. Rilpivirine-LA formulation: pharmacokinetics in plasma, genital tract in HIV-females and rectum in males. Presented at: The 19th Conference on Retroviruses and Opportunistic Infections. Seattle, WA, USA, 5-8 March 2012.
8. Altice FL, Kamarulzaman A, Soriano V V, Schechter M, Friedland GH. Treatment of medical, psychiatric, and substance-use comorbidities in people infected with HIV who use drugs. Lancet 376(9738), 367-387 (2010).
9. Kozal MJ, Amico KR, Chiarella J et al. HIV drug resistance and HIV transmission risk behaviors among active injection drug users. J. Acquir. Immune Defc. Syndr. 40(1), 106-109 (2005). (Pubitemid 41233214)
10. Chesney MA, Ickovics JR, Chambers DB et al. Self-reported adherence to antiretroviral medications among participants in HIV clinical trials: the AACTG adherence instruments. Patient Care Committee &Adherence Working Group of the Outcomes Committee of the Adult AIDS Clinical Trials Group (AACTG). AIDS Care 12(3), 255-266 (2000).
11. Tang MF, Lei L, Guo SR, Huang WL. Recent progress in nanotechnology for cancer therapy. Chin. J. Cancer 29(9), 775-780 (2010).
12. Hu CM, Zhang L. Nanoparticle-based combination therapy toward overcoming drug resistance in cancer. Biochem. Pharmacol. 83(8), 1104-1111 (2012).
13. Trono D, Van Lint C, Rouzioux C et al. HIV persistence and the prospect of long-term drug-free remissions for HIV-infected individuals. Science 329(5988), 174-180 (2010).
14. Dash P, Gorantla S, Roy U et al. Long-acting nanoformulated antiretroviral therapy elicits potent antiretroviral and neuroprotective responses in HIV-1-infected humanized mice. AIDS 26(17), 2135-2144 (2012).
15. Kanmogne GD, Singh S, Roy U et al. Mononuclear phagocyte intercellular crosstalk facilites transmission of cell targeted nanoformulated antiretroviral drugs to human brain endothelia l cells. Int. J. Nanomedicine 7, 2373-2388 (2012).
16. Bainbridge WS. Public attitudes toward nanotechnology. J. Nanopart. Res. 4(6), 561-570 (2002). (Pubitemid 135713449)
17. Bottini M, Rosato N, Gloria F et al. Public optimism towards nanomedicine. Int. J. Nanomedicine 6, 3473-3485 (2011).